比较最新药物对改善阿尔茨海默病患者认知功能的疗效：系统综述和网络荟萃分析。

IF 2.9 3区医学 Q2 NEUROSCIENCES

Neuroscience Pub Date : 2024-11-15 DOI:10.1016/j.neuroscience.2024.11.029

Weili Cao, Bo Zhu, Zhiqin Liu, Xiaotao Jia, Hongwei Zhao, Naibing Gu, Hongye Chang, Jing Xi, Rong Li, Kun Guo, Jia Shen, Le Ding, Fanya Sun, Zhengli Di

{"title":"比较最新药物对改善阿尔茨海默病患者认知功能的疗效：系统综述和网络荟萃分析。","authors":"Weili Cao, Bo Zhu, Zhiqin Liu, Xiaotao Jia, Hongwei Zhao, Naibing Gu, Hongye Chang, Jing Xi, Rong Li, Kun Guo, Jia Shen, Le Ding, Fanya Sun, Zhengli Di","doi":"10.1016/j.neuroscience.2024.11.029","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The recent emergence of updated drugs for the treatment of Alzheimer’s disease (AD) has produced encouraging cognitive and clinical results in clinical trials, but there is still controversy over how to choose effective treatment options among these numerous drugs. The purpose of this network meta-analysis (NMA) is to compare and rank these drugs based on their efficacy.</div></div><div><h3>Methods</h3><div>We systematically searched in PubMed, Web of Science databases and Cochrane LIbrary, gov for randomized controlled trials for data from 2020 to 2024, and then performed a random-effect network meta-analysis.</div></div><div><h3>Results</h3><div>Our NMA results showed that in several main indicators ADAS-cog, CDR-SB and ADCS-ADL. GV-971 (MD −2.36, 95 % CI −5.08, 0.35), Lecanemab (MD −2.00, 95 % CI −5.25, 1.26), Donanemab (MD −1.45, 95 % CI −4.70, 1.81), Masupirdine (MD −0.83, 95 % CI −3.49, 1.84) were more effective than placebo in improving ADAS-cog. In terms of CDR-SB, Lecanemab (MD −3.11,95 % CI −5.23, −0.99) was more effective. Compared with placebo, Donanemab was more effective in ADCS-ADL (MD 3.26,95 % CI 1.48,5.05). SUCRA values showed that GV-971 (76.1 % and 68.7 %) could achieve better therapeutic effects in ADAS-cog) and NPI, and Lecanema (98.1 %) was more effective in improving CDR-SB scores than other drugs. Donanemab (99.8 %) may be the most promising way to slow down the decline in ADCS-ADL scores. The effect of Masupirdine (80.7 %) on MMSE was significantly better than that of several other drugs.</div></div><div><h3>Conclusion</h3><div>Donanemab and Lecanemab showed good efficacy in ADCS-ADL and CDR-SB, respectively. GV-971 is the best choice to improve ADAS cogs and NPI.</div></div>","PeriodicalId":19142,"journal":{"name":"Neuroscience","volume":"565 ","pages":"Pages 29-39"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer ’s disease: A systematic review and network meta- analysis\",\"authors\":\"Weili Cao, Bo Zhu, Zhiqin Liu, Xiaotao Jia, Hongwei Zhao, Naibing Gu, Hongye Chang, Jing Xi, Rong Li, Kun Guo, Jia Shen, Le Ding, Fanya Sun, Zhengli Di\",\"doi\":\"10.1016/j.neuroscience.2024.11.029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The recent emergence of updated drugs for the treatment of Alzheimer’s disease (AD) has produced encouraging cognitive and clinical results in clinical trials, but there is still controversy over how to choose effective treatment options among these numerous drugs. The purpose of this network meta-analysis (NMA) is to compare and rank these drugs based on their efficacy.</div></div><div><h3>Methods</h3><div>We systematically searched in PubMed, Web of Science databases and Cochrane LIbrary, gov for randomized controlled trials for data from 2020 to 2024, and then performed a random-effect network meta-analysis.</div></div><div><h3>Results</h3><div>Our NMA results showed that in several main indicators ADAS-cog, CDR-SB and ADCS-ADL. GV-971 (MD −2.36, 95 % CI −5.08, 0.35), Lecanemab (MD −2.00, 95 % CI −5.25, 1.26), Donanemab (MD −1.45, 95 % CI −4.70, 1.81), Masupirdine (MD −0.83, 95 % CI −3.49, 1.84) were more effective than placebo in improving ADAS-cog. In terms of CDR-SB, Lecanemab (MD −3.11,95 % CI −5.23, −0.99) was more effective. Compared with placebo, Donanemab was more effective in ADCS-ADL (MD 3.26,95 % CI 1.48,5.05). SUCRA values showed that GV-971 (76.1 % and 68.7 %) could achieve better therapeutic effects in ADAS-cog) and NPI, and Lecanema (98.1 %) was more effective in improving CDR-SB scores than other drugs. Donanemab (99.8 %) may be the most promising way to slow down the decline in ADCS-ADL scores. The effect of Masupirdine (80.7 %) on MMSE was significantly better than that of several other drugs.</div></div><div><h3>Conclusion</h3><div>Donanemab and Lecanemab showed good efficacy in ADCS-ADL and CDR-SB, respectively. GV-971 is the best choice to improve ADAS cogs and NPI.</div></div>\",\"PeriodicalId\":19142,\"journal\":{\"name\":\"Neuroscience\",\"volume\":\"565 \",\"pages\":\"Pages 29-39\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0306452224006110\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306452224006110","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

背景：最近，治疗阿尔茨海默病（AD）的新药不断涌现，在临床试验中取得了令人鼓舞的认知和临床结果，但如何在众多药物中选择有效的治疗方案仍存在争议。本网络荟萃分析（NMA）的目的是根据疗效对这些药物进行比较和排序：我们在 PubMed、Web of Science 数据库和 Cochrane LIbrary、gov 中系统检索了 2020 年至 2024 年的随机对照试验数据，然后进行了随机效应网络荟萃分析：GV-971（MD -2.36，95 % CI -5.08，0.35）、Lecanemab（MD -2.00，95 % CI -5.25，1.26）、Donanemab（MD -1.45，95 % CI -4.70，1.81）、Masupirdine（MD -0.83，95 % CI -3.49，1.84）在改善ADAS-cog方面比安慰剂更有效。就 CDR-SB 而言，Lecanemab（MD -3.11，95 % CI -5.23，-0.99）更为有效。与安慰剂相比，多奈单抗在 ADCS-ADL 方面更有效（MD 3.26，95 % CI 1.48，5.05）。SUCRA 值显示，GV-971（76.1% 和 68.7%）在 ADAS-cog）和 NPI 方面的疗效更好，Lecanema（98.1%）在改善 CDR-SB 评分方面比其他药物更有效。多奈单抗（99.8%）可能是最有希望减缓 ADCS-ADL 评分下降的方法。Masupirdine（80.7%）对MMSE的效果明显优于其他几种药物：结论：多那尼单抗和来卡尼单抗分别在 ADCS-ADL 和 CDR-SB 方面显示出良好的疗效。GV-971是改善ADAS cogs和NPI的最佳选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer ’s disease: A systematic review and network meta- analysis

Background

The recent emergence of updated drugs for the treatment of Alzheimer’s disease (AD) has produced encouraging cognitive and clinical results in clinical trials, but there is still controversy over how to choose effective treatment options among these numerous drugs. The purpose of this network meta-analysis (NMA) is to compare and rank these drugs based on their efficacy.

Methods

We systematically searched in PubMed, Web of Science databases and Cochrane LIbrary, gov for randomized controlled trials for data from 2020 to 2024, and then performed a random-effect network meta-analysis.

Results

Our NMA results showed that in several main indicators ADAS-cog, CDR-SB and ADCS-ADL. GV-971 (MD −2.36, 95 % CI −5.08, 0.35), Lecanemab (MD −2.00, 95 % CI −5.25, 1.26), Donanemab (MD −1.45, 95 % CI −4.70, 1.81), Masupirdine (MD −0.83, 95 % CI −3.49, 1.84) were more effective than placebo in improving ADAS-cog. In terms of CDR-SB, Lecanemab (MD −3.11,95 % CI −5.23, −0.99) was more effective. Compared with placebo, Donanemab was more effective in ADCS-ADL (MD 3.26,95 % CI 1.48,5.05). SUCRA values showed that GV-971 (76.1 % and 68.7 %) could achieve better therapeutic effects in ADAS-cog) and NPI, and Lecanema (98.1 %) was more effective in improving CDR-SB scores than other drugs. Donanemab (99.8 %) may be the most promising way to slow down the decline in ADCS-ADL scores. The effect of Masupirdine (80.7 %) on MMSE was significantly better than that of several other drugs.

Conclusion

Donanemab and Lecanemab showed good efficacy in ADCS-ADL and CDR-SB, respectively. GV-971 is the best choice to improve ADAS cogs and NPI.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neuroscience 医学-神经科学

CiteScore

6.20

自引率

0.00%

发文量

394

审稿时长

52 days

期刊介绍： Neuroscience publishes papers describing the results of original research on any aspect of the scientific study of the nervous system. Any paper, however short, will be considered for publication provided that it reports significant, new and carefully confirmed findings with full experimental details.